1-3 of 3
Barbara Biedrzycki
Close
Sort by
Journal Articles

K562/GM-CSF Vaccination Reduces Tumor Burden, Including Achieving Molecular Remissions, in Chronic Myeloid Leukemia (CML) Patients with Residual Disease on Imatinib Mesylate (IM).

B. Douglas Smith, MD, Yvette L. Kasamon, MD, Carole B. Miller, MD, Christina Chia, MD, Kathleen Murphy, PhD, Jeanne Kowalski, PhD, Irena Tartakovsky, MS, Barbara Biedrzycki, AOCN/CRNP, Richard J. Jones, MD, Kristen Hege, MD, Hyam I. Levitsky, MD
Journal: Blood
Blood (2005) 106 (11): 2858.
https://doi.org/10.1182/blood.V106.11.2858.2858
Published: 2005
Journal Articles

Characterization of Vaccine Site and Cellular Infiltrate in Subjects with Chronic Myeloid Leukemia (CML) Receiving K562/GM-CSF Vaccination in Combination with Imatinib Mesylate with or without Topical Imiquimod.

Christina Y. Chia, MD, B. Douglas Smith, MD, Yvette Kasamon, MD, Carole B. Miller, MD, Mary E. Brummet, MS, Lora Bankova, MD, Jeanne Kowalski, PhD, Barbara Biedrzycki, MSN, Kristen Hege, Lisa A. Beck, MD, Hyam Levitsky, MD
Journal: Blood
Blood (2005) 106 (11): 2399.
https://doi.org/10.1182/blood.V106.11.2399.2399
Published: 2005
Journal Articles

Autologous Tumor Combined with a GM-CSF-Secreting Cell Line Vaccine (GVAX®) Following Autologous Stem Cell Transplant (ASCT) in Multiple Myeloma.

Ivan Borrello, Barbara Biedrzycki, Nicole Sheets, Beena George, Frederick Racke, Kathy Loper, Kimberly Noonan, Amy Donnelly, Kristen Hege, Hyam Levitski
Journal: Blood
Blood (2004) 104 (11): 440.
https://doi.org/10.1182/blood.V104.11.440.440
Published: 2004